The article informs about a study conducted by Arteaga et al. to identify a relationship between All-trans retinoic acid (ATRA), a therapy to treat acute promyelocytic leukemia, and PHR8, a specific interacting factor, by over-expressing retinoic acid receptor alpha in vitro environment.